Bionomics Limited (NASDAQ:BNOX) Sees Large Increase in Short Interest

Bionomics Limited (NASDAQ:BNOX) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 120,400 shares, a growth of 12.4% from the August 31st total of 107,100 shares. Based on an average trading volume of 901,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC bought a new position in Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent quarter. Institutional investors and hedge funds own 15.90% of the company’s stock.

Bionomics Price Performance

NASDAQ:BNOX traded down $0.21 during mid-day trading on Monday, reaching $0.43. The company’s stock had a trading volume of 1,143,474 shares, compared to its average volume of 451,118. The firm’s fifty day moving average price is $0.64 and its two-hundred day moving average price is $0.81. Bionomics has a 12-month low of $0.42 and a 12-month high of $5.30.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Bionomics in a report on Thursday, August 1st.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.